Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250730 | 1.00 | GAA (0.44) | GAASMN1; SMN2HRH3KIF11NR3C1 | |
| SCHEMBL19614572 | 1.00 | GAA (0.44) | GAASMN1; SMN2HRH3KIF11NR3C1 | |
| SCHEMBL507791 | 0.86 | GAA (0.43) | GAASMN1; SMN2HRH3KIF11NR3C1 | |
| SCHEMBL18997059 | 0.83 | GAA (0.42) | GAASMN1; SMN2HRH3KIF11NR3C1 | |
| SCHEMBL30117086 | 0.80 | MGLL (0.45) | — | |
| SCHEMBL26099561 | 0.80 | MGLL (0.45) | — | |
| SCHEMBL20353279 | 0.79 | HRH3 (0.46) | GAASMN1; SMN2HRH3ALDH1A1CYP2A6 | |
| SCHEMBL105821 | 0.78 | ALDH1A3 (0.47) | GAASMN1; SMN2HRH3ALDH1A1CYP2A6 | |
| SCHEMBL17707975 | 0.76 | ACHE (0.41) | KIF11NR3C1ALDH1A1SLC6A9CA1 | |
| SCHEMBL506514 | 0.76 | TRPA1 (0.40) | NR3C1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294491-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| EP-4342889-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| WO-2023002965-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-01-26 | — | — | WO | disclosed |
| EP-4058147-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd (JP) | 2022-09-21 | — | — | EP | disclosed |
| CN-114829351-A | Novel antimalarial agents containing heterocyclic compounds | 卫材R&D管理有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021149692-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021149692-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | QDPR, DHODH, THPO | GAA 1943/4885SMN1; SMN2 3627/4885HRH3 300/4885 |
| US-20240294491-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | REN, RCC1, LSS | GAA 700/4885SMN1; SMN2 3979/4885HRH3 1307/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | GAA 527/4885SMN1; SMN2 210/4885HRH3 594/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | GAA 527/4885SMN1; SMN2 210/4885HRH3 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.